Key Insights

• Insiders appear to have a vested interest in Heidelberg Pharma's growth, as seen by their sizeable ownership

• The top 2 shareholders own 81% of the company

• Ownership research, combined with past performance data can help provide a good understanding of opportunities in a stock

A look at the shareholders of Heidelberg Pharma AG (ETR:HPHA) can tell us which group is most powerful. With 46% stake, individual insiders possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).

So it follows, every decision made by insiders of Heidelberg Pharma regarding the company's future would be crucial to them.

Let's delve deeper into each type of owner of Heidelberg Pharma, beginning with the chart below.

View our latest analysis for Heidelberg Pharma

What Does The Institutional Ownership Tell Us About Heidelberg Pharma?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

Since institutions own only a small portion of Heidelberg Pharma, many may not have spent much time considering the stock. But it's clear that some have; and they liked it enough to buy in. If the business gets stronger from here, we could see a situation where more institutions are keen to buy. When multiple institutional investors want to buy shares, we often see a rising share price. The past revenue trajectory (shown below) can be an indication of future growth, but there are no guarantees.

Hedge funds don't have many shares in Heidelberg Pharma. Our data shows that Dietmar Hopp is the largest shareholder with 46% of shares outstanding. Huadong Medicine Co., Ltd is the second largest shareholder owning 35% of common stock, and Polar Capital Holdings Plc holds about 1.9% of the company stock.

A more detailed study of the shareholder registry showed us that 2 of the top shareholders have a considerable amount of ownership in the company, via their 81% stake.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is some analyst coverage of the stock, but it could still become more well known, with time.

Insider Ownership Of Heidelberg Pharma

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.